Patients with refractory chronic lymphocytic leukaemia (CLL) still have an unfavourable prognosis and novel treatment strategies are necessary, preferably adjusted to the patient's individual situation. Refractoriness is no longer limited just to fludarabine (F) but extends to F-combinations with other chemotherapeutic agents (e.g. cyclophosphamide [C] and FC) and antibodies (e.g. rituximab [R], FR, and FCR). Also, refractoriness to alemtuzumab is an increasing problem. New pharmacological developments provide promising approaches. This review focuses on novel therapies such as monoclonal antibodies and small molecules aiming at specific targets of the CLL cell in the refractory situation. Approved therapeutic regimens will be presented as well as investigational approaches. An overview of completed and current clinical trials is offered.
Introduction
Although much progress has been made on the treatment of chronic lymphocytic leukaemia (CLL) over the last few decades, this disease is still incurable. For more than 20 years the purine analogue fludarabine (F) has shown efficiency in CLL therapy. In 1989 the results of a clinical trial on fludarabine as monotherapy in pretreated CLL patients were published. The response data and toxicity profile were very promising [Keating et al. 1989] . At that time there were no hints as to which patients would respond to fludarabine and which would not. Today the combination of fludarabine, cyclophosphamide and rituximab (FCR) is the gold standard for the first-line treatment of CLL patients without relevant comorbidities. Mainly two clinical trials contributed to this progress: long-term results of a phase 2 trial in 300 untreated patients showed an overall response rate (ORR) of 95%, 72% complete remission (CR) and 23% partial remission (PR). The median follow up was 6 years.
Six-year overall and failure-free survival was 77% and 51% [Tam et al. 2008] . The phase III CLL8 trial of the German CLL Study Group (GCLLSG) compared the former standard FC to the immunochemotherapeutic regimen FCR. The CR rate was significantly higher for the immunochemotherapy group (44% versus 22%, p < 0.001), progression-free survival (PFS) was improved (65% versus 45% at 3 years, p < 0.001), and for the first time also extended overall survival (87% versus 83% at 3 years, p ¼ 0.01) was achieved [Hallek et al. 2010] .
Refractory CLL
Patients who did not achieve at least a PR or who progressed within 6 months to the last therapy are considered refractory [Hallek et al. 2008] . In CLL, refractoriness is mostly related to purine analogue regimens, especially F-based regimens, even though more recently we have to face also refractoriness to additional agents such as the CD52 antibody alemtuzumab. So far the mechanisms of treatment refractoriness in CLL are only partially understood. It is important to underline that stem cell transplantation (SCT) could be indicated in the patient population targeted by this review. However, SCT, similarly to other 'novel' agents such as bendamustine is somewhat outside the scope of this review (focused on novel targeted therapies) and can by no means comprehensively covered due to space limitations.
Analysis of the genetic background of CLL patients revealed an association between F refractoriness and alterations in the short arm of chromosome 17 where TP53 is located, also called the 'guardian of the genome'. Fludarabine treatment results in an activation of the p53-mediated apoptotic pathway. In a multivariate analysis of 100 patients with chronic B-cell leukemias (B-cell chronic lymphocytic leukaemia [B-CLL] , B-cell prolymphocytic leukaemia [B-PLL] and Waldenströ m's macroglobulinemia) deletion of the TP53 gene was the strongest prognostic factor for survival. Importantly, this genetic alteration also predicted nonresponse to purine analogue treatment [Dohner et al. 1995 ]. An analysis of TP53 mutations was recently performed on a large cohort of 375 patients who were recruited in a randomized prospective trial on F versus fludarabine plus cyclophosphamide (FC) as firstline treatment (the CLL4 trial of the GCLLSG). Data confirmed the TP53 mutation's poor impact on the prognosis regardless of the presence of a 17p deletion. Median PFS (23.3 versus 62.2 months) as well as overall survival (29.2 versus 84.6 months) were significantly decreased in patients with TP53 mutation compared with those without the mutation (Figure 1 ) ].
Monoclonal antibodies

Rituximab
The IgG1 monoclonal anti-CD20 antibody rituximab has a chimeric structure: its light-and heavy-chain variable regions are murine, the constant regions of human origin. Rituximab is well established in the treatment of B-cell lymphomas and part of the gold standard of CLL first-line therapy FCR. Its strength in CLL is in combination rather than single treatment. The use of rituximab in CLL therapy is reviewed in detail by Jaglowski and Byrd [Jaglowski and Byrd, 2010 ].
FCR has not only been examined in primary therapy but also in the refractory situation. A total of 177 pretreated patients were included in a recent study: 82% of them had fludarabine as prior treatment, 21% were refractory to fludarabine. ORR was 73%, CR was achieved in 25%, nodular PR in 16% and PR in 32% of the cases. In the group of fludarabine refractory cases, ORR was 58%. In the multivariate analysis treatment failure was associated with fludarabine refractoriness [Wierda et al. 2005] .
Pentostatin is supposed to be less myelosuppressive than fludarabine. In a phase II study the combination of rituximab with cyclophosphamide and pentostatin was examined in 46 patients of whom 32 had pretreated CLL. In the CLL cases ORR was 75%, CR rate was 25%; 75% of fludarabine refractory patients responded. Infections of grade 3 or 4 occurred in 28% of the cases. All in all, this regimen was well tolerated. About 72% of the patients received six cycles of therapy at full dose [Lamanna et al. 2006 ].
In vitro synergistic effects of a combination of fludarabine, cytarabine and cisplatin [Li et al. 1997; Wang et al. 1991] led to a phase I/II study for patients with Richter syndrome or fludarabine refractoriness. Thirty fludarabine refractory patients were included of whom 33% responded; 7% of CR was achieved in this group. Adverse events were mainly grade 3 or 4 neutropenia and thrombocytopenia [Tsimberidou et al. 2008] .
The combination of rituximab with HD-methylprednisolone has been tested in 14 patients with refractory disease. ORR was 93% (all but one patient responded), CR rate was 36%, and the safety profile well tolerable [Castro et al. 2008 ]. Another 14 heavily pretreated patients (13 of whom with fludarabine) were treated with this combination. Again, the ORR was 93%, but only two CR and one nodular PR were achieved. The only patient with 17p-deletion did not respond. Infectious complications, especially opportunistic infections (candida, aspergillus, viral infections) were the most serious adverse events. Eight patients died during the study [Dungarwalla et al. 2008] . All in all rituximab in combination with HD-methylprednisolone seems to be effective but is associated with serious infectious risks.
In a phase II study the combination with hyper-CVXD (cyclophosphamide, vincristine, liposomal daunorubicine, dexamethasone) showed activity but also high toxicity in 30 cases of Richter syndrome or fludarabine refractoriness. Nineteen patients with refractory CLL were treated: 37% of them achieved either a CR (one patient) or a PR (six patients). The toxicity profile was unfavourable: 11 patients died during the first 2 cycles mainly of systemic fungal and bacterial infections. Myelosuppression was the most common adverse event [Tsimberidou et al. 2003 ].
Meanwhile new anti-CD20 antibodies are under development or have already entered clinical trials: the type I CD20 antibody ofatumumab and the type II antibody GA-101. Type I anti-CD20 antibodies such as rituximab or ofatumumab lead to redistribution of the CD20 antigen into lipid rafts. They exert complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), but low direct apoptosis induction. Type II antibodies such as the novel antibody GA-101 do not fix complement. They act via direct cell death induction through homotypic aggregation and mediate ADCC (Figure 2 ).
Alemtuzumab
The humanized monoclonal IgG1 antibody alemtuzumab is directed against the CD52 antigen on mature lymphocytes. It was approved in the USA and EU for the treatment of fludarabine refractory CLL in 2001. Since 2008 this drug is also approved for first-line treatment of patients who are ineligible for fludarabine containing therapies, i.e. those with 17p deletion or TP53 mutation.
A large multicentre trial in the USA and Europe of intravenous alemtuzumab administration showed better survival data for patients with fludarabine refractory CLL compared with historic cohorts. A total of 93 patients who were fludarabine refractory were enrolled in that prospective noncomparative phase II trial. ORR was 33%, CR was achieved in 2%; 7% of the patients had a CR except for cytopenia. The most [Keating et al. 2002] .
The CLL2H trial of the GCLLSG showed that subcutaneous administration of alemtuzumab is as effective as intravenous infusion in fludarabine refractory CLL. The ORR was 34% with 4% of CR ( Figure 3 ). Importantly, side effects of infusion reactions were markedly reduced. Efficiency was the same in all genetic subgroups, notably in 17p and 11q deletion, TP53 mutation and unmutated immunoglobulin heavy chain variable (IGHV) status [Stilgenbauer et al. 2009 ]. The CLL2O trial of the GCLLSG and FCGCLL/ MW aims to achieve a higher remission rate by adding high-dose dexamethasone (40 mg) to subcutaneous alemtuzumab and to prolong remission duration and survival by either allogeneic SCT or alemtuzumab maintenance. An interim analysis of 50 patients who completed induction therapy with either F-refractory disease or 17pdeletion (untreated or at relapse) showed an ORR of 47% for the F-refractory cohort. No patient in this cohort achieved a complete remission. Estimated overall survival at 12 months was 54%. At a median follow up at 41.9 weeks, 2 patients died due to progressive disease and 5 due to infection ].
Ofatumumab
Ofatumumab is a fully human IgG1 antibody. Like rituximab it is a type I monoclonal antibody and targets the CD20 antigen on the surface of B-lymphocytes. Nevertheless ofatumumab binds to an epitope that is distinct from rituximab: the small extracellular loop and the N-terminal region of the large extracellular loop of CD20. Its location is closer to the membrane which may contribute to stronger CDC [Teeling et al. 2006 [Teeling et al. , 2004 .
Two clinical trials were essential for the approval of ofatumumab in refractory CLL by the US Food and Drug Administration (FDA) in 2009. In a multicentre dose-escalating study, 33 patients with relapsed or refractory CLL were included. The maximum tolerated dose was not reached; 2000 mg weekly doses were well tolerated. Infusion-related events such as transient rigor, pyrexia, increased sweating, fatigue or rash occurred mostly during the first administration of ofatumumab. Infectious complications were seen in 51% of the cases, most of them were of grade 1 or 2. One infectious interstitial lung disease was fatal. Neutropenia or thrombocytopenia was seen in 15% of the patients. The cohort treated with the highest dose achieved a remission rate of 50%. There were no CR [Coiffier et al. 2008 ].
An interim analysis of a large international multicentre trial [ClinicalTrials.gov identifier: NCT00349349] also showed that ofatumumab is well tolerated and clinically active in the refractory situation. The analysis was based on the data of 59 patients with fludarabine and alemtuzumab refractory CLL (FA-ref) and 79 patients with fludarabine refractory CLL with bulky disease (BF-ref) where alemtuzumab is supposed to be less effective. The ORR was 58% for the FA-ref group and 47% for the BF-ref group (Figure 4) . One CR was achieved in a patient with bulky disease. Importantly rituximab pretreatment did not have an influence on the response rates. There, the ORR was 54% in the FA-ref patients and 44% in the BF-ref cases. Distinct clinical improvement was achieved in patients with baseline thrombocytopenia or anemia and decreased Eastern Cooperative Oncology Group (ECOG) performance status. Adverse events were similar to those of the dose-escalating study cited above: frequently infusion-related events and infectious complications. The ORR in 17p-deleted cases was lower [Wierda et al. 2010 ].
GA-101
The structure of GA-101 is quite different from conventional monoclonal anti-CD20 antibodies.
It is a humanized IgG1 monoclonal antibody with a glyco-engineered Fc region. As a type II antibody GA-101 induces direct cell death (caspase-independent apoptosis) rather than CDC. 
Bevacizumab (Avastin)
The humanized monoclonal IgG1 antibody bevacizumab (Avastin) is approved for the treatment of several solid tumour entities such as metastatic colon cancer and non-small cell lung cancer.
It binds to vascular endothelial growth factor (VEGF) and is an inhibitor of angiogenesis. The results of a first phase I trial of flavopiridol in refractory or relapsed CLL were disappointing. Thirteen patients were included and treated with a 24-hour continuous infusion every 2 weeks. Doses were 80 up to 140 mg/m 2 . There were no remissions seen [Flinn et al. 2005 ].
The protein binding capacity of flavopiridol in foetal bovine serum is much lower than in human serum. Therefore, the doses for clinical use had been underestimated. Considering pharmacokinetics the administration schedule was changed for the next phase I trial in refractory CLL (n ¼ 52). Flavopiridol was administered as a 30-minute loading dose followed by a 4-hour continuous infusion. Doses ranged from 30 to 50 mg/m 2 with loading doses of 3040 mg/m 2 . Tumour lysis syndrome became a problem in 30 cases and caused one death. The most frequent adverse events were neutropenia, diarrhoea and cytokine release syndrome. A total of 40% of the patients achieved a PR, the median PFS was 12 months. Also patients with high-risk cytogenetics (17p or 11q deletion) responded [Phelps et al. 2009 ]. In a phase II study prophylactic dexamethasone was added on each treatment day to prevent the cytokine release syndrome. The cycle length was reduced well as the number of treatments per cycle. This improved the tolerability of the regimen [Lin et al. 2009 ]. An interim analysis of a phase II study of flavopiridol showed clinical responses in patients with fludarabine refractory CLL. A total of 108 patients were treated; using the NCI-96 criteria for response assessment, 31% achieved a partial response. Also patients with high-risk cytogenetics such as the 17p or 11q deletion had a benefit. No complete responses were seen. The most serious adverse events were infections (32%), tumour lysis syndrome (19%), diarrhoea (17%) and febrile neutropenia (15%). Three cases of death seemed to be related to flavopiridol treatment (colitis, pseudomonal sepsis and tumour lysis syndrome) [Lanasa et al. 2010] . Analysis of 112 patients of a phase I and phase II trial of single-agent flavopiridol in relapsed or refractory patients revealed no significant difference in the overall survival; also patients with high-risk cytogenetics show a high ORR. Nevertheless the estimated PFS by 24 months was lower in patients with poor risk cytogenetics (17p, 4%, and 11q, 5%, versus other cytogenetics, 24%) [Woyach et al. 2010 ].
SNS-032
Another Cdk-inhibitor is SNS-032 which inhibits Cdk2, Cdk7 and Cdk9 [Conroy et al. 2009 ].
In vitro studies showed more potent inhibition of RNA synthesis and cell death induction by SNS-032 than by flavopiridol. Levels of Mcl-1 and XIAP were reduced whereas Bcl-2 was not affected [Chen et al. 2009 ]. Results of a phase I study in patients with advanced CLL and multiple myeloma were published in 2010. Nineteen patients with CLL were included. All of them were heavily pretreated, 26% were fludarabine refractory. The dose-limiting toxicity for CLL patients was tumour lysis syndrome, the maximum tolerated dose was 75 mg/m 2 and myelosuppression was the most frequent toxicity of grade 3 or 4. One patient achieved a reduction of more than 50% in measurable disease (without improvement in haematological parameters), whereas one patient had stable disease. All in all, clinical activity was limited even though in vitro biomarker analyses showed inhibition of Cdk7 and Cdk7, CLL cell apoptosis and decreases in Mcl-1 and XIAP levels [Tong et al. 2010] .
One trial of intravenous SNS-032 in patients with advanced (not necessarily refractory) B-lymphoid malignancies is currently ongoing but not recruiting [ClinicalTrials.gov identifier: NCT00446342].
Lenalidomide
Lenalidomide is well established in the treatment of multiple myeloma and showed therapeutic efficiency in MDS. This immune-modulating drug (IMID) is a structural analogue of thalidomide. It is supposed to be more potent than thalidomide and to bear less side effects (fatigue and neuropathy) but has also teratogenic properties. Its mode of action is not fully understood. Direct cell killing has not been detected in CLL cells so far. As an immune modulating drug lenalidomide causes activation of T and NK cells and therefore indirect cell death induction [Corral et al. 1999] . It inhibits cytokines such as tumour necrosis factor alpha (TNFa), In clinical trials a typical side effect of lenalidomide is quite common: the tumour flare reaction. The tumour flare reaction can mimic disease progression and is characterized by a sudden increase in lymph node size, painful lymphadenopathy, bone pain, rash and pyrexia. In most cases it can be dissolved by nonsteroidal antiinflammatory drugs or steroids.
Two phase II trials showed the efficacy of lenalidomide also in refractory CLL: 45 patients were included and treated with 25 mg p.o. on 21 days of a 28-day cycle. A total of 51% of the patients were refractory to fludarabine. The ORR was 47% with a CR rate of 9%. Fatigue (83%) and tumour flare reaction (58%) were the most common nonhaematological adverse events. Myelosuppression was a common treatmentrelated toxicity [Chanan-Khan et al. 2006 ].
In the second study 44 patients with relapsed or refractory CLL were enrolled. A dose-escalating schedule was chosen with a starting dose of 10 mg for 28 days and dose escalation in steps of 5 mg per cycle up to 25 mg. An ORR of 32% was achieved with a CR rate of 7%, nodular PR in 2% and PR in 23%. A total of 39% of the patients had progress during the treatment. Myelosuppression was the most common adverse event. No tumour lysis syndrome was observed, but tumour flare reactions occurred in 12% of the cases [Ferrajoli et al. 2008] .
ABT-263
ABT-263 also called navitoclax is an orally bioavailable small-molecule BH3-mimetic. Like the proapoptotic BH3-only proteins, it binds to the antiapoptotic members of the Bcl-2 family Bcl-2, Bcl-XL and Bcl-w and prevents their binding to the proapoptotic molecules Bax and Bak. Therefore, the mitochondrial apoptotic pathway is activated.
In most in vitro experiments ABT-737 a structure analogue of ABT-263 was used which is not orally bioavailable and metabolically unstable. In primary CLL cells, ABT-737 induced apoptosis at an EC50 of 7 nm after 4 hours of incubation [Vogler et al. 2008] . In whole blood assays ABT-263 had an EC50 of more than 10 mM after 4 hours of incubation, whereas in human serum free assays the EC50 was less than 1 mM. In human plasma the agent is highly bound to albumin [Vogler et al. 2010] . This fact has to be considered for the planning of clinical trials with ABT-263.
The interim analysis of a phase I/IIa trial of ABT-263 in 21 patients with relapsed or refractory CLL showed an ORR of 33%. No CRs were achieved but PRs were confirmed radiographically in two patients, eight patients had a stable disease and two were progressive. To prevent thrombocytopenia caused by Bcl-XL inhibition, a loading dose of 100 mg was administered for 7 days followed by a continuous dose of up to 300 mg daily for 21 days. The most common adverse events were diarrhoea (52%), nausea (44%), vomiting (24%), fatigue (24%), thrombocytopenia (20%) and neutropenia (12%) [Roberts et al. 2009 ].
This trial is still recruiting [ClinicalTrials.gov identifier: NCT00481091], another one for refractory CLL is going to test the combination of ABT-263 with FCR or BR [ClinicalTrials.gov identifier: NCT00868413].
AT-101
AT-101 is another BH3 mimetic. It is an enantiomer of gossypol (R(À)-gossypol) which binds to the BH3 motif of Bcl-2, Bcl-xL and Mcl-1. Gossypol is extracted from cotton plant seeds.
In vitro studies showed that gossypol as well as AT-101 induce cell death in primary CLL cells. Concentrations used were quite high at 10 and 30 mM for gossypol and 20 mM for AT-101 [Balakrishnan et al. 2009 [Balakrishnan et al. , 2008 . 
Talabostat mesylate (PT-100)
Talabostat is an orally bioavailable dipeptidyl peptidase inhibitor with antineoplastic and haematopoesis stimulating properties. It inhibits the activation of fibroblast activation protein (FAP) which is essential for development, growth and metastasis of epithelial tumours [Kraman et al. 2010 ] but is also found in the stroma of lymphoid tissue. In xenograft models of human CD20 þ Bcell lymphoma talabostat increased the cytotoxic activity of rituximab [Adams et al. 2004 ].
Talabostat interacts with bone marrow stromal cells and stimulates haematopoiesis via increased cytokine production (granulocyte colony stimulating factor [G-CSF], IL-6 and IL-11) [Jones et al. 2003 ]. In vitro studies in primary CLL cells showed apoptosis induction at least in a subset of primary CLL samples [Danilov et al. 2005] . A phase II trial is currently studying the potential of combined talabostat and rituximab in CLL relapsed after fludarabine pretreatment or in the F-refractory situation [ClinicalTrials.gov identifier: NCT00086203].
Obatoclax
The Bcl-2 inhibition capacity of the small-molecule obatoclax is broader than that of ABT-263. Apart from Bcl-2, Bcl-XL and Bcl-w it also binds to Mcl-1 which is known to be overexpressed in CLL. In vitro Mcl-1 can cause resistance to the Bcl-2 inhibitor ABT-737 which can be overcome by obatoclax [Nguyen et al. 2007] .
In a phase I study in 26 patients with advanced CLL and fludarabine pretreatment, one PR was achieved. The maximum tolerated dose was 28 mg/m 2 over 3 hours every 3 weeks. Haemoglobin levels and platelet counts were improved; lymphocyte counts were reduced in 18 of 26 patients. Dose-limiting adverse events were infusion related neurologic symptoms such as somnolence, ataxia and euphoria [O'Brien et al. 2009b] . Obatoclax seems to be attractive for combination therapy with its modest singleagent activity and tolerable safety profile.
Oblimersen
Oblimersen is a synthetic antisense oligonucleotide which targets the first six codons of the Bcl-2 mRNA. In vitro studies showed decreased Bcl-2 mRNA expression and synergistic effects with fludarabine [Marcucci et al. 2005] , rituximab [Loomis et al. 2003 ] and alemtuzumab [Cotter et al. 2003 ]. In a phase I/II trial in patients with relapsed or refractory CLL modest single-agent activity was shown with a PR in 8% of the patients. Circulating lymphocytes were reduced by more than 50% in 50% of the cases. The maximum tolerated dose based on the phase I part of the study was 3 mg/kg/day. A cytokine release reaction within 2448 hours during the first two cycles with high fever, hypotension and back pain was dose limiting [O'Brien et al. 2005] .
A phase III trial compared the conventional FC-regimen with the combination of oblimersen and FC in 241 patients. Oblimersen was intravenously administered at a dose of 3 mg/kg/day via continuous infusion for the first 7 days of a cycle of 28 days. Indeed the CR rate was significantly higher in the experimental arm (17% versus 7%, p ¼ 0.025). Also the duration of response was longer (>36 versus 22 months, p ¼ 0.03). The 5-year survival rate of the responders with complete or partial response were 47% in the experimental arm and 24% in the FC arm (p ¼ 0.038). Fludarabine-sensitive patients had the greatest benefit [O'Brien et al. 2009a ].
HSP90 inhibitors
HSP90 plays an important role in the regulation of cell signalling, proliferation and survival. As an ATP-dependent chaperone, it regulates the folding, stabilization and activation of a broad range of proteins (so-called 'clients') involved in cell survival and proliferation, such as glucorticoid receptors, transcription factors, kinases as well as the tumour suppressor protein p53 [Taipale et al. 2010; Picard, 2002] . The ansamycin antibiotic geldanamycin is an ATP-competitive inhibitor of HSP90. In vitro experiments showed selective toxicity of geldanamycin towards CLL and normal B cells at nanomolar concentrations, whereas T cells and CD34þ bone marrow haematopoietic progenitor cells were unaffected . In another study in ATM/p53 mutated primary CLL cells, overexpressed mutated p53 was downregulated in response to HSP90 inhibition, whereas wildtype p53 was upregulated [Lin et al. 2008] . ZAP70 was shown to be another client of HSP90 that is degraded after HSP90 inhibition by the geldanamycin derivates 17-AAG and 17-DMAG [Castro et al. 2005] . Synergistic effects were seen in primary CLL cells with the combination of rituximab and 17-AAG or 17-DMAG [Johnson et al. 2007 ]. HSP90 inhibitors may be of particular value for the treatment of TP53 mutated cases. 17-DMAG is cytotoxic to CLL cells, but not normal lymphocytes, and acts as an NFkB inhibitor by depletion of the HSP90 client IKK. This leads to decreased NFkB target gene transcription and caspase-dependent cell death [Hertlein et al. 2010] . Another novel HSP90 inhibitor, SNX7081, seems to be more potent than 17-AAG. SNX7081 sensitizes ATM/p53 mutated CLL cells to fludarabine treatment and overcomes fludarabine resistance in vitro [Best and Mulligan, 2010] . 
GA-101
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Conclusion
Refractory chronic lymphocytic leukaemia represents a clinical challenge. Novel treatment approaches include antibody-based therapies as well as the use of small molecules, often in combination with established chemotherapeutic regimens. Approved for the refractory situation are the CD52 antibody alemtuzumab and, in the case of fludarabine and alemtuzumab refractoriness, the CD20 antibody ofatumumab. In the fludarabine refractory situation alemtuzumab treatment led to an overall response rate of 33%. The most promising and advanced new agents are the CDK inhibitor flavopiridol and the immunomodulating drug lenalidomide. Response rates of 3050% were seen in singlecentre experiences. A broad range of other novel drugs are still under development or in early phases of clinical trials. The results are eagerly awaited considering the still unfavourable prognosis of refractory CLL. Nevertheless new therapeutic regimens have to prove not only efficacy but also tolerability.
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